Liquidia Reports Strong Q1 Profitability and YUTREPIA Sales Growth
LQDA has more than doubled off its 52-week low of $11.85.
Summary
Liquidia reported its third consecutive profitable quarter with strong Q1 2026 financial results, driven by robust YUTREPIA sales and a significant increase in cash reserves.
Key Events · Earnings and Guidance · LQDA
-
Record Profitability
Reported net income of $52.9 million and adjusted EBITDA of $71.2 million for Q1 2026, marking the third consecutive profitable quarter.
-
Strong YUTREPIA Sales
Achieved $129.9 million in net product sales for YUTREPIA, driven by over 4,500 unique patient prescriptions and approximately 3,750 patients treated since launch.
-
Enhanced Financial Position
Increased cash and cash equivalents by $32.1 million to $222.8 million as of March 31, 2026.
-
Clinical Pipeline Advancement
Progressed Phase 4 studies for YUTREPIA and initiated the pivotal Phase 3 Re-Spire study for L606.
Analysis · LQDA · Life Sciences
Liquidia Corporation announced robust first-quarter results, demonstrating accelerating profitability with a significant increase in net income and adjusted EBITDA. The continued strong performance of YUTREPIA, evidenced by substantial sales and patient uptake, is driving this financial strength. The company's cash position also improved considerably, providing a solid foundation for ongoing clinical development.
At the time of this filing, LQDA was trading at $43.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.7B. The 52-week trading range was $11.85 to $46.67. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.